TG Therapeutics Inc.

TGTX

Held by 6 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

6 funds opened new positions. Next phase3 readout (Ublituximab): Oct 2026. Short interest: 28.4% of float.

Catalysts

Phase 2Q2 2015UblituximabNon-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's MacroglobulinemiaNCT01647971

Primary: Number of Participants with Adverse Events as a Measure of Safety and Tolerability (Subjects will be followed for 4 weeks)Enrollment:39/39Sites: 8NA, TREATMENT

Phase 2Q4 2015UblituximabChronic Lymphocytic Leukemia, Mantle Cell LymphomaNCT02013128

Primary: To evaluate the safety of ublituximab in combination with ibrutinib in patients with select B-cell malignancies (28 days (1 cycle of therapy))Enrollment:66/66Sites: 18NA, TREATMENT

Phase 2PositiveQ3 2017UblituximabMultiple SclerosisNCT02738775

Primary: Responder Rate of B-Cell Depletion at Week 4 (Week 4)Enrollment:49/49Sites: 12RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2020UblituximabChronic Lymphocytic LeukemiaNCT02301156

Primary: Overall Response Rate (ORR) (Up to 62 months)Enrollment:126/126Sites: 88RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2020UblituximabRelapsing Multiple Sclerosis (RMS)NCT03277261

Primary: Annualized Relapse Rate (ARR) (Up to 96 weeks)Enrollment:549/549Sites: 14RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2020UblituximabRelapsing Multiple Sclerosis (RMS)NCT03277248

Primary: Annualized Relapse Rate (ARR) (Up to 96 weeks)Enrollment:545/545Sites: 13RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ2 2021UmbralisibChronic Lymphocytic LeukemiaNCT02742090

Primary: Progression-free Survival (From Day 1 to the earlier of the first documentation of definitive disease progression or death (Up to 61.7 months))Enrollment:51/51Sites: 15NA, TREATMENT

Phase 2PositiveQ1 2022UmbralisibMarginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin LymphomaNCT03364231

Primary: Overall Response Rate (ORR) as Assessed by Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) and Consensus-Based 6th International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (Every 3 cycles (1 Cycle = 28 days) from Day 1 Cycle 1 up to approximately 4.2 years)Enrollment:21/21Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2022UblituximabFollicular Lymphoma, Small Lymphocytic LymphomaNCT03828448

Primary: Overall Response Rate (ORR) (Up to 22 months)Enrollment:34/34Sites: 3NA, TREATMENT

Phase 2NegativeQ2 2022UblituximabChronic Lymphocytic LeukemiaNCT04016805

Primary: Rate of Undetected Minimal Residual Disease (U-MRD) (Up to approximately 23 months)Enrollment:41/41Sites: 3NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2022TGR-1202Chronic Lymphocytic Leukemia, Non Hodgkin LymphomaNCT03207256

Primary: Adverse Events of TGR-1202 and/or TGR-1202 + ublituximab treatment, including delayed toxicities (Evaluated at each planned visit through study completion, an average of 2 years)Enrollment:51/51Sites: 17NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2022VenetoclaxChronic Lymphocytic Leukemia, Non-Hodgkin LymphomaNCT03379051

Primary: Determine Acceptable Adverse Events That Are Related to Treatment (12 months)Enrollment:78/78Sites: 3NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2022UblituximabChronic Lymphocytic LeukemiaNCT02656303

Primary: Overall Response Rate (ORR) as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria (Up to 76 months)Enrollment:116/116Sites: 87NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ2 2022UblituximabDiffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone LymphomaNCT02793583

Primary: Overall Response Rate (Every 8-12 weeks, up to 2 years)Enrollment:710/710Sites: 168RANDOMIZED, TREATMENT

Phase 2Q4 2022UblituximabRelapsing Remitting Multiple SclerosisNCT03381170

Phase 3NegativeQ4 2022UblituximabChronic Lymphocytic Leukemia, Small Lymphocytic LymphomaNCT03801525

Phase 3NegativeQ1 2023ObinutuzumabChronic Lymphocytic LeukemiaNCT02612311

Phase 3Q4 2026UblituximabRelapsing Multiple SclerosisNCT07211633

Primary: Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab (Up to Week 24)Enrollment:Target 360Sites: 42RANDOMIZED, TREATMENT

Phase 2Q2 2027UblituximabMultiple SclerosisNCT07503873

Phase 3Q4 2027UblituximabRelapsing Multiple SclerosisNCT05877963

Phase 2Q3 2028UblituximabMyasthenia GravisNCT07673744

Phase 2Q4 2028UblituximabSchizophreniaNCT07680946

Phase 3Q1 2030UblituximabRelapsing Multiple SclerosisNCT07220252

Primary: Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab (Predose and multiple timepoints up to Week 24)Enrollment:Target 240RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2032UblituximabRelapsing Multiple Sclerosis (RMS)NCT04130997

TG Therapeutics Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research